Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Risk Categories for Patients with Atypical CML Evaluated

Am J Hematol; 2017 Jun; Patnaik, Barraco, et al

It may be useful to group patients with atypical chronic myeloid leukemia (aCML) into certain risk categories, according to a study involving 25 individuals.

Participants—all with aCML—were a median of 70 years of age. All had gene mutations, and more than one-third had cytogenetic abnormalities. Among the results:

  • Median overall survival was ~11 months.
  • At a median follow-up of 11 months, 68% had died, and 8% experienced leukemic transformations.
  • Survival was adversely impacted by advanced age; low hemoglobin; red blood cell transfusion dependence; high white blood cell count; TET2, NRAS, PTPN11 mutations; and the presence of ≥3 gene mutations.
  • In multivariable analysis, age >67; low hemoglobin; and TET2 mutations retained prognostic significance.


Patnaik M, Barraco D, Lasho T, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol. 2017;92(6):542-548. doi:10.1002/ajh.24722.